Linda Garland

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    J Thorac Oncol 6:1938-45. 2011
  2. ncbi Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor
    Linda Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    J Immunother 28:376-81. 2005
  3. ncbi A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:4274-82. 2006
  4. ncbi A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:5182-9. 2006
  5. ncbi Chemotherapy for malignant pleural mesothelioma
    Linda L Garland
    Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Curr Treat Options Oncol 12:181-8. 2011
  6. ncbi Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study
    H H Sherry Chow
    Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA
    Cancer Prev Res (Phila) 3:1168-75. 2010
  7. ncbi Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma
    Nam P Nguyen
    Department of Radiation Oncology, University of Arizona, 1501 N Campbell Avenue, Tucson, AZ, USA
    Cancer Treat Rev 34:719-27. 2008
  8. ncbi Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
  9. ncbi Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
    Linda L Garland
    University of Arizona Cancer Center, Tucson, AZ, USA
    J Clin Oncol 25:2406-13. 2007
  10. ncbi Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy
    Paul B Jacobsen
    Psychosocial and Palliative Care Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Pain Symptom Manage 28:7-18. 2004

Detail Information

Publications10

  1. ncbi Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    J Thorac Oncol 6:1938-45. 2011
    ..We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy...
  2. ncbi Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor
    Linda Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    J Immunother 28:376-81. 2005
    ..027 mg/m2. NBI-3001 at 0.016 mg/m2 was well tolerated. Low circulating levels of NBI-3001, coupled with rising NAB titers, may have contributed to the lack of response in tumors that express IL-4R...
  3. ncbi A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:4274-82. 2006
    ..We conducted a dose escalation study of CI-1033 with docetaxel to assess the safety profile and pharmacokinetics of the combination and to establish the maximum tolerated dose...
  4. ncbi A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:5182-9. 2006
    ..We conducted a dose escalation study of HMN-214 in patients with advanced cancer to assess the safety profile and pharmacokinetics of HMN-214 and to establish the maximum tolerated dose...
  5. ncbi Chemotherapy for malignant pleural mesothelioma
    Linda L Garland
    Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Curr Treat Options Oncol 12:181-8. 2011
    ..Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy...
  6. ncbi Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study
    H H Sherry Chow
    Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA
    Cancer Prev Res (Phila) 3:1168-75. 2010
    ..Further clinical development of resveratrol for cancer prevention should consider evaluation of lower doses of resveratrol to minimize adverse metabolic drug interactions...
  7. ncbi Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma
    Nam P Nguyen
    Department of Radiation Oncology, University of Arizona, 1501 N Campbell Avenue, Tucson, AZ, USA
    Cancer Treat Rev 34:719-27. 2008
    ..Stereotactic body radiation therapy may become standard of care for operable early stages non-small cell lung cancer...
  8. ncbi Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  9. ncbi Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
    Linda L Garland
    University of Arizona Cancer Center, Tucson, AZ, USA
    J Clin Oncol 25:2406-13. 2007
    ..We conducted a phase II trial of the EGFR TKI erlotinib in previously untreated patients with MPM...
  10. ncbi Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy
    Paul B Jacobsen
    Psychosocial and Palliative Care Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Pain Symptom Manage 28:7-18. 2004
    ..These findings suggest that, in addition to previously reported relationships with fatigue, declines in hemoglobin levels during chemotherapy treatment are associated with adverse changes in cognitive functioning...